{"id":190216,"date":"2021-02-19T08:18:05","date_gmt":"2021-02-19T06:18:05","guid":{"rendered":"https:\/\/fendaf.ee\/uncategorized-et-en\/vaktsineerimise-korvalmojud\/"},"modified":"2026-10-16T23:15:48","modified_gmt":"2026-10-16T20:15:48","slug":"vaktsineerimise-korvalmojud","status":"publish","type":"post","link":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/","title":{"rendered":"Dog vaccination side effects: what studies show and how to assess your dog\u2019s risk"},"content":{"rendered":"<p>Dog vaccination side effects can range from a mild, temporary reaction to a rare severe reaction. Vaccination helps prevent serious infectious diseases, but no medical intervention is entirely risk-free. The question is not whether vaccination is \u201cgood\u201d or \u201cbad\u201d, but how to give an individual dog the protection they need while minimising unnecessary risk.<\/p>\n<p><!--more--><\/p>\n<p>FendaF\u2019s central question is: what do we actually know, what choices are available, and what do they mean in a particular dog\u2019s everyday life?<\/p>\n<h2>Questions we are still seeking answers to<\/h2>\n<p>Researching this article left several important questions open for dog owners. Some concern the limits of published research, some concern individual products, and others concern making a reasoned decision when a dog has complex health needs. Not finding a sufficiently detailed public answer does not, by itself, mean that the relevant studies have never been conducted.<\/p>\n<ul>\n<li>Which dose-finding studies support the full dose of each vaccine, and have smaller doses been studied? The immunological rationale for using the same dose does not tell us exactly what has been tested for each product.<\/li>\n<li>How well were very small, elderly and chronically ill dogs represented in safety studies? What evidence can help assess the individual risk for an elderly dog with heart disease, for example?<\/li>\n<li>How much adjuvant, stabiliser and manufacturing residue does a particular product contain, and which studies help assess their significance for dogs of different sizes and health status? The presence of an ingredient alone does not establish that it is harmful.<\/li>\n<li>How long does rabies protection last in an elderly dog vaccinated repeatedly throughout life, and how much additional benefit does the next dose offer? Protection lasting 10\u201312 years or longer after the final dose remains a clearly identified hypothesis, not an established duration of protection.<\/li>\n<li>How is an individual case handled in Estonia when a dog has a serious underlying illness or a previous severe vaccine reaction, but their rabies vaccination is due? We need clarification from the competent authority about the practical procedure; the question does not imply that legislation provides a general exemption on grounds of illness.<\/li>\n<li>Who is responsible and compensates for harm if a correctly administered mandatory rabies vaccine causes serious injury to a dog, but no error by the manufacturer or veterinarian is identified? We need clarification from the competent authority about possible grounds for compensation and the procedure involved.<\/li>\n<\/ul>\n<p>Clarifying these questions requires answers from manufacturers and the competent authorities and, where necessary, additional research data. We will update the article as answers become available. Below, we distinguish existing evidence, its limitations and questions that remain unresolved.<\/p>\n<h2>The key points at a glance<\/h2>\n<table style=\"border-collapse:collapse;width:100%\">\n<tbody>\n<tr>\n<th style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">What we know<\/th>\n<th style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">What we cannot conclude<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">Acute post-vaccination adverse events are recorded more often in smaller dogs.<\/td>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">This does not establish that a smaller vaccine dose would be adequate or safer.<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">Several vaccines at one visit are associated with more recorded adverse events.<\/td>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">This does not mean that every combination or every dog automatically requires separate appointments.<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">Leptospirosis vaccine safety data are nuanced and depend on the study and product.<\/td>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">L2\/L4 reporting rates do not establish that L4 is a fixed multiple more dangerous for an individual dog.<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">Health, previous reactions and actual exposure risk are part of the decision.<\/td>\n<td style=\"border:1px solid #d9d9d9;padding:12px;text-align:left\">\u201cGenerally safe\u201d does not mean \u201crisk-free\u201d for an individual dog.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>What reactions can occur after vaccination?<\/h2>\n<p>Most post-vaccination reactions are mild and temporary. A dog may be more tired than usual, the injection site may be tender or swollen, and temporary loss of appetite, fever, vomiting or diarrhoea may occur. Hypersensitivity reactions, including hives, facial swelling or anaphylaxis, occur less often.<\/p>\n<p>It is important to distinguish a symptom that occurs after vaccination, a suspected vaccine adverse reaction, and an adverse reaction for which a causal link to the vaccine is sufficiently supported. Timing is an important clue, but does not establish causation on its own.<\/p>\n<p>If suspected reactions go undocumented, recurring patterns may remain invisible to medicine safety monitoring. A suspicion therefore deserves documenting even when a causal relationship has not yet been established.<\/p>\n<h2>How common are dog vaccination side effects?<\/h2>\n<p>A retrospective study published by Moore and colleagues in 2005 included 1,226,159 dogs and 3,439,576 vaccine doses. Within three days of vaccination, 4,678 suspected vaccine-associated adverse events were diagnosed: 38.2 events per 10,000 vaccinated dogs. Events included nonspecific vaccine reactions, allergic reactions, hives and anaphylaxis.<\/p>\n<p>A much larger dataset published in 2023 included 4,654,187 dogs and 16,087,455 vaccination visits. A suspected adverse event was recorded after 31,197 visits, or 19.4 per 10,000 vaccination visits. Rates were highest in dogs weighing up to 5 kg and in certain breeds, particularly French Bulldogs and Dachshunds.<\/p>\n<p>These overall figures should not be interpreted as evidence that the frequency of adverse reactions halved over time. The 2005 study used vaccinated dogs as its denominator; the 2023 study used vaccination visits. The study periods, products and other circumstances also differed.<\/p>\n<p>The shared message is that risk is not the same for every dog. Both studies primarily examined acute events documented within three days. They therefore cannot fully answer questions about possible later health problems.<\/p>\n<h2>Why do small and large dogs receive the same vaccine dose?<\/h2>\n<p>Vaccine dosing differs from the dosing of many medicines. A vaccine needs to present enough antigen to the immune system to generate a protective response. The amount of antigen required does not necessarily increase in proportion to body weight.<\/p>\n<p>This explains why dogs of different sizes receive the same vaccine dose, but does not answer every question: a vaccine contains more than antigen. Depending on the product, it may contain adjuvants, stabilisers and manufacturing residues. The 2024 WSAVA guidelines themselves note that some manufacturers have reduced concentrations of certain excipients or introduced smaller injection volumes containing the same amount of antigen.<\/p>\n<p>If a 2 kg dog and an 80 kg dog receive the same absolute quantity of a component, the quantity per kilogram is 40 times higher in the smaller dog. That does not establish a 40-fold increase in health risk. Risk depends on the substance, its biological effects and the mechanism of the reaction. It is nevertheless a reasonable research question, especially given the higher adverse-event rates in small dogs in large datasets.<\/p>\n<h2>Could a small dog receive a smaller vaccine dose?<\/h2>\n<p>The 2024 WSAVA guidelines address this directly. They acknowledge that post-vaccination adverse events are more common in small dogs and that small dogs may produce higher antibody titres following a standard dose than large and giant breeds.<\/p>\n<p>However, WSAVA does not recommend giving a small dog half or a quarter of the manufacturer\u2019s specified dose. The reason is practical and evidence-based: adequate protection from reduced doses cannot be assumed across all vaccines, and the manufacturer\u2019s full dose remains standard practice.<\/p>\n<p>There is an important distinction here. Insufficient evidence that a smaller dose is effective is not evidence that a smaller dose could never work. WSAVA also identifies the needs of very small and very large dogs as an area requiring further research.<\/p>\n<p>A manufacturer-developed 0.5 ml vaccine must also be distinguished from independently injecting half of a vaccine intended to be given as a 1 ml dose. These are not scientifically or legally equivalent situations.<\/p>\n<h2>Does giving several vaccines on the same day increase risk?<\/h2>\n<p>In the 2005 study, the recorded adverse-event risk increased with the number of vaccine doses given at one visit. Each additional vaccine dose was associated with an approximately 27% relative increase in dogs weighing up to 10 kg, and approximately 12% in dogs weighing more than 10 kg.<\/p>\n<p>This is not an increase of 27 percentage points. If the starting risk were 1%, for example, a 27% relative increase would mean a risk of approximately 1.27%.<\/p>\n<p>The 2023 study confirmed the same broad pattern: recorded adverse-event rates increased as one to four vaccines were administered at the same visit. The risk was particularly notable in small dogs receiving several vaccines together.<\/p>\n<p>This does not prove that all vaccines should always be given on different days. For a small dog, a dog with a previous severe reaction, or a dog with complex health needs, it does justify discussing whether combining every required vaccine into one appointment is the best choice.<\/p>\n<p>A combination vaccine and several vaccines given at one visit are different things. A combination vaccine contains components against several diseases in one product: DAP, for example, protects against distemper, adenovirus and parvovirus. A dog might also receive a separate rabies or leptospirosis vaccine at the same appointment. The studies above do not, by themselves, establish that every combination vaccine is more dangerous than administering its components separately.<\/p>\n<h3>What do Peter Dobias and Judy Morgan recommend?<\/h3>\n<p>Peter Dobias recommends reducing or avoiding combination vaccines where possible, not administering several vaccines together, and leaving at least four weeks between rabies vaccination and other injections. This is his integrative clinical recommendation, rather than an official administration rule that applies to every product.<\/p>\n<p>His reasoning is that simultaneous exposure to antigens from several pathogens may place excessive demands on the immune system, whereas separate vaccination allows the body to focus on one response at a time. His puppy guide describes a single-antigen parvovirus vaccine followed by distemper vaccination four weeks later. This explains his reasoning, but \u201coverload\u201d is his interpretation here: the source does not provide a controlled comparison demonstrating that an authorised combination vaccine harms a healthy dog\u2019s immune system.<\/p>\n<p>Judy Morgan also recommends avoiding several vaccinations at the same time and choosing vaccines according to the dog\u2019s health, lifestyle and exposure risk. Her concern is reducing unnecessary administrations and possible adverse effects, particularly in an animal with a previous reaction. Possible long-term health effects she describes are not established causal relationships on the basis of clinical opinion alone.<\/p>\n<p>In a 2016 article, Morgan recommends leaving at least 3\u20134 weeks or longer between booster doses. Her reasoning is that the immune response following vaccination takes weeks to develop and closely spaced repetitions may provide no additional benefit. This mainly concerns the timing of repeat doses; it cannot be turned into a universal requirement to leave exactly 28 days between any two different vaccines.<\/p>\n<p>Morgan should not, however, be described as rejecting every combination vaccine. Her 2023 guide with Rachel Fusaro includes a DAP combination vaccine. It also describes a preference for separate components for their own pets under certain lower-risk conditions. Dobias and Morgan therefore share precautionary principles, but their protocols are not identical.<\/p>\n<h3>What does a four-week interval help us assess?<\/h3>\n<p>A practical advantage of separate appointments is the opportunity to observe the dog before the next vaccination and to narrow down the suspected product if a reaction occurs. This is a reasonable consideration, but does not establish that a four-week interval reduces the total adverse-event risk across all required doses. Fewer administrations at one appointment and the overall risk of the complete schedule are different questions.<\/p>\n<p>The conventional veterinary view is that a healthy dog\u2019s immune system can respond to several antigens at once; each component\u2019s protective efficacy must be demonstrated for a combination vaccine to be authorised. The 2024 WSAVA guidelines allow 2\u20134-week intervals in puppy core vaccination. This does not support a blanket claim that intervals shorter than four weeks are always harmful. Demonstrated efficacy does not, however, mean that every dog has the same adverse-reaction risk.<\/p>\n<p>For FendaF, the practical question remains: which components does this dog need now, is some protection already present, and could the necessary vaccinations reasonably be separated? In puppies especially, delaying protection can prolong susceptibility to infection. The schedule must fit the product information, the dog\u2019s exposure risk and, for rabies, Estonian legal requirements.<\/p>\n<h2>Can a chronically ill dog be vaccinated?<\/h2>\n<p>FendaF also discusses this issue in \u201c<a href=\"https:\/\/fendaf.ee\/tervis\/miks-haige-looma-vaktsineerimine-on-ohtlik\/\">Why can vaccinating a sick animal be dangerous?<\/a>\u201d An overly absolute conclusion should be avoided here too: a chronic diagnosis does not automatically mean a dog cannot be vaccinated.<\/p>\n<p>A stable chronic condition needs to be distinguished from acute or unstable illness. With heart disease, for example, the severity of heart failure, arrhythmias, breathing symptoms, medication, the dog\u2019s general condition and the infection requiring protection may all influence the decision.<\/p>\n<p>The 2024 WSAVA guidelines also address dogs with a previous severe post-vaccination reaction. For certain core vaccines, a previously appropriately vaccinated dog may still be protected, and serological testing can be considered where needed. For rabies, WSAVA emphasises local legal requirements and consultation with the competent authority where necessary.<\/p>\n<p>A low adverse-event rate across the general population does not tell us the precise risk for one dog with a serious underlying condition. Individual benefit and risk require a separate assessment.<\/p>\n<h2>How long does a vaccine actually protect a dog?<\/h2>\n<p>A booster\u2019s due date is not necessarily the day immunity ends. Three things need distinguishing: the duration of protection established in the product information, the interval recommended in professional guidelines, and an individual dog\u2019s actual immunity. Rabies also involves a legal obligation. These may overlap, but do not mean the same thing.<\/p>\n<p>A study assessing protection three years after vaccination can demonstrate protection lasting at least three years. If dogs are not followed for longer, it does not show that protection disappears in year four. Likewise, long-lasting protection in one study group does not guarantee the same duration for every dog or every vaccine.<\/p>\n<h3>What do Schultz\u2019s long-term immunity data show?<\/h3>\n<p>Ronald Schultz\u2019s 2006 review distinguishes challenge studies, in which vaccinated dogs encounter disease-causing virus, from serology, which measures antibodies. It reports the following findings for modified-live core vaccines:<\/p>\n<ul>\n<li>Canine distemper virus (CDV): at least 7 years by challenge and 15 years by serology for the Rockborn and Snyder Hill strains; at least 5 and 9 years respectively for Onderstepoort. These are not universal durations for all distemper vaccines.<\/li>\n<li>Canine adenovirus (CAV): at least 7 years by challenge and 9 years by serology. Protection against infectious hepatitis from CAV-2 vaccination was assessed using CAV-1 virus.<\/li>\n<li>Canine parvovirus (CPV-2): at least 7 years by challenge and 9 years by serology.<\/li>\n<\/ul>\n<p>Detectable antibodies after 15 years do not equal 15-year protection demonstrated by challenge. Nor is year seven a known expiry date for immunity. These are durations studied, and interpretation depends on the vaccine, methods and dogs involved.<\/p>\n<p>Schultz and colleagues\u2019 2010 paper describes CDV, CAV and CPV immunity in dogs not revaccinated for up to nine years: they had antibodies associated with protection and resisted infection and\/or disease in challenge studies. This supports long-term immunity, but does not establish the duration for every current product or individual dog.<\/p>\n<p>The 2024 WSAVA guidelines also note a limitation: some details of Schultz\u2019s extensive experiments were not published in full. Long-term findings should therefore be considered alongside limitations in transparency and generalisability. CDV\/CAV\/CPV findings cannot automatically be applied to leptospirosis or kennel cough vaccines.<\/p>\n<h3>Rabies and the Rabies Challenge Fund findings<\/h3>\n<p>In 2020, Dodds, Larson, Christine and Schultz published a study in which dogs received rabies vaccines at 12 and 15 weeks of age. In later challenge experiments, survival was: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7088826\/\">Study<\/a><\/p>\n<ul>\n<li>4 of 5 dogs, or 80%, at 6 years and 7 months after vaccination;<\/li>\n<li>6 of 12 dogs, or 50%, at 7 years and 1 month;<\/li>\n<li>1 of 5 dogs, or 20%, at 8 years.<\/li>\n<\/ul>\n<p>These were small, separate groups, not repeated measurements of the same dogs; the eight-year group also received a different vaccine. The percentages therefore do not describe a universal protection-decay curve. The virus used in the first challenge experiment was insufficiently virulent; the figures above come from subsequent experiments.<\/p>\n<p>A separate revaccination experiment demonstrated a memory response after 6 years and 1 month, including at very low previous titres. Immune memory does not, however, guarantee that a protective response will develop quickly enough following infection. The findings demonstrate long-lasting protection in some dogs, rather than assured seven-year protection in every dog.<\/p>\n<h3>Hypothesis: an elderly dog\u2019s protection may persist for 10\u201312 years or longer after the final dose<\/h3>\n<p>Could an elderly dog vaccinated against rabies repeatedly throughout life remain protected for 10\u201312 years or longer after the final dose? This is a biologically possible hypothesis: a booster can reactivate immune memory. However, these specific durations have not been established in long-term canine challenge studies. More doses do not guarantee progressively longer protection, and age, health and previous immune responses may affect the outcome.<\/p>\n<p>This is therefore a research question that existing data do not yet answer reliably. It cannot serve as a guarantee of protection for an individual dog or replace legal rabies vaccination requirements.<\/p>\n<h2>Can titre testing replace revaccination?<\/h2>\n<p>FendaF\u2019s article \u201c<a href=\"https:\/\/fendaf.ee\/tervis\/immuniseerimine-ei-ole-sama-mis-vaktsineerimine\/\">Immunisation is not the same as vaccination<\/a>\u201d also discusses this distinction.<\/p>\n<p>For distemper, parvovirus and adenovirus, a positive antibody test can provide strong evidence of existing protection. A negative or low titre does not always mean that all immune memory is absent: routine titre tests do not measure every protective mechanism of the immune system.<\/p>\n<p>Leptospirosis antibody titres cannot be used as such a straightforward marker of protection. For rabies, biological protection must also be distinguished from legal vaccination status. The presence of antibodies does not automatically replace Estonia\u2019s statutory vaccination requirement.<\/p>\n<p>A titre describes the blood sample at that time; it does not predict when protection will expire. Reliable antibody detection supports protection in an adult dog that has previously mounted an active immune response to CDV, CAV or CPV. The size of the number alone cannot tell us how many years of protection remain. Results and cut-offs from different tests may not be directly comparable.<\/p>\n<p>A negative result leaves protection uncertain. A dog should not automatically be considered protected on the assumption that immune memory remains: WSAVA recommends revaccination in this situation. With a previous severe reaction or other complex health needs, the next step should be chosen with the veterinarian. Confirmation in a reference laboratory can be helpful, especially for CDV and CAV, because point-of-care tests differ in accuracy. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/jsap.13718\">WSAVA 2024<\/a><\/p>\n<p>The practical question is therefore whether another dose against this particular disease is needed now, or whether measuring existing protection could help the decision. Rabies protection must still be considered alongside the legal requirements discussed below.<\/p>\n<h2>Puppy vaccination and maternally derived antibodies<\/h2>\n<p>During the first weeks of life, a puppy receives protection from maternal antibodies. These decline over time, at a rate that differs between puppies. Maternal antibodies can protect a puppy from disease while also preventing a vaccine from inducing the intended immune response.<\/p>\n<p>This can create a \u201cwindow of susceptibility\u201d: maternal protection is no longer sufficient, while vaccination may not yet work fully. This uncertainty is why puppies receive repeated vaccinations. WSAVA recommends that the final core vaccine dose in the puppy series be administered at 16 weeks of age or older.<\/p>\n<p>The 2024 WSAVA guidelines then recommend either antibody testing at least four weeks after the final puppy-series dose or an additional core vaccine dose at 26 weeks of age or older. This reduces the time spent unprotected by puppies whose earlier responses were still blocked by maternal antibodies. If serology confirms protection against distemper, adenovirus and parvovirus, the additional 26-week dose is unnecessary.<\/p>\n<p>Integrative discussions have also raised the question of whether very early vaccination might affect maternal antibody dynamics. Current evidence does not justify presenting this as an established general mechanism.<\/p>\n<h2>Leptospirosis vaccines: what do L2 and L4 mean?<\/h2>\n<p>Leptospirosis is a bacterial infection that can cause severe kidney and liver damage in dogs. It is a zoonosis, meaning that it can also endanger people. Leptospira bacteria include many serovars, organised into serogroups.<\/p>\n<p>L2 and L4 refer to the number of Leptospira components represented in the vaccine. European L4 vaccines generally cover the Icterohaemorrhagiae, Canicola, Grippotyphosa and Australis serogroups. Broader coverage does not mean protection against every possible Leptospira serovar.<\/p>\n<p>When assessing efficacy, look at what a study actually measured: reduced clinical disease, reduced infection, prevention of kidney damage or reduced bacterial shedding in urine. These are different outcomes.<\/p>\n<h3>Faddu\u2019s experience<\/h3>\n<p>Faddu developed leptospirosis despite previous vaccination. His longer story appears in FendaF\u2019s article \u201c<a href=\"https:\/\/fendaf.ee\/en\/health\/kennel-cough-and-leptospirosis\/\">Kennel cough and leptospirosis: two different diseases and Faddu\u2019s long recovery<\/a>\u201d.<\/p>\n<p>Faddu\u2019s rapid test was positive, while later serological tests performed in Germany were negative. He received doxycycline and recovered. This single case cannot establish which Leptospira serovar caused his illness, whether it belonged to a vaccine-covered group, or whether vaccination made the illness milder.<\/p>\n<p>It does show why \u201cprotects\u201d should not be interpreted as an absolute guarantee. A vaccine\u2019s effect depends, among other things, on coverage of the specific pathogen, the immune response, time since vaccination and diagnostic limitations.<\/p>\n<h2>Does L4 cause more side effects than L2?<\/h2>\n<p>According to the UK Veterinary Medicines Directorate\u2019s (VMD) March 2026 update, the combined reported adverse-event incidence was 0.016% for L2 products and 0.040% for L4 products. Calculated from these published percentages, that means approximately 1.6 animals with reported adverse events per 10,000 estimated animals treated for L2, and 4 per 10,000 for L4. The calculation uses affected animals, not simply the number of reports: one report can cover several animals.<\/p>\n<p>These are not risk estimates from a controlled clinical trial. VMD calculations use pharmacovigilance reports and an estimated number of treated animals. Cases may include simultaneous use of several products, off-label use or symptoms later attributed to another possible cause. VMD explicitly notes that a report following a product\u2019s use does not establish causation.<\/p>\n<p>The figures 0.016% and 0.040% therefore do not establish that L4 is 2.5 times more dangerous for an individual dog. The safety observation should nevertheless not simply be dismissed. VMD recommends an individual vaccination programme agreed by owner and veterinarian, considering local leptospirosis risk and the potential added benefit of L4\u2019s broader coverage.<\/p>\n<p>I think it is also worth remembering health changes that appear later. If a problem develops a month or two after vaccination, a possible connection may go unnoticed and unreported. That does not mean that the later problem was necessarily caused by the vaccine. A reasonable suspicion still deserves documenting and reporting, even when causation has not been confirmed.<\/p>\n<h2>What does the 2015 leptospirosis study show?<\/h2>\n<p>A retrospective study in 2015 examined 130,557 dogs. Owner-reported adverse events were recorded within five days of vaccination.<\/p>\n<p>Across the vaccinations studied, the owner-reported adverse-event rate was 26.3 per 10,000 dogs. Among dogs receiving a Leptospira vaccine alone or with other vaccines, it was 53.0 per 10,000. Receiving a leptospirosis vaccine was associated with a higher overall likelihood of an adverse event.<\/p>\n<p>Hypersensitivity reactions were uncommon, at 6.5 per 10,000 dogs, and their frequency did not differ significantly between dogs that did and did not receive a leptospirosis vaccine.<\/p>\n<p>This does not prove that all current leptospirosis vaccines are more dangerous than other vaccines. Newer datasets, products, vaccine combinations and reporting practices differ. The more defensible conclusion is that historical concerns about reactogenicity cannot automatically be applied to every current product, while earlier safety observations should not simply be erased.<\/p>\n<h2>What do integrative veterinarians emphasise?<\/h2>\n<p>Judy Morgan and Peter Dobias emphasise individual decisions based on the dog\u2019s health, vaccination history, existing immunity, exposure risk and previous suspected reactions. They question automatic calendar-based vaccination and administering several products at one appointment.<\/p>\n<p>Some of this closely aligns with conventional guidelines and large datasets. Considering the higher recorded adverse-event risk in small dogs, previous severe reactions and existing immunity is well supported.<\/p>\n<p>Other proposed mechanisms or links with long-term disease require stronger direct evidence. Clinical experience is not the same as a controlled study, but it can provide a valuable observation and the starting point for a research question.<\/p>\n<p>FendaF\u2019s aim is not to remove either perspective from the discussion. We need to distinguish controlled evidence, biologically plausible mechanisms, clinical experience and hypotheses.<\/p>\n<h2>Rabies vaccination in Estonia: what does the law currently require?<\/h2>\n<p>Rabies vaccination is mandatory for dogs in Estonia. Under the current regulation on detailed measures for rabies prevention and control, the keeper must ensure their dog is vaccinated, with the first vaccination given by 21 weeks of age at the latest.<\/p>\n<p>Revaccination follows the vaccine leaflet, but the interval must not exceed 24 months from the previous vaccination. A manufacturer\u2019s evidence of longer immunity in another context does not override the maximum interval specified in Estonian law.<\/p>\n<p>Section 3 of the current regulation does not provide a general illness-based exemption from the obligation to vaccinate dogs against rabies. In cases involving serious underlying illness, a previous severe reaction or another exceptional circumstance, it is therefore sensible to request the Agriculture and Food Board\u2019s official position on the individual case, rather than assume either an automatic exemption or that no option could exist.<\/p>\n<h2>Why does manufacturer transparency matter?<\/h2>\n<p>Mandatory rabies vaccination raises another important question. When the state requires owners to vaccinate their dogs, how much information should owners be able to obtain about how a particular product\u2019s dose was determined and which dogs were included in safety studies?<\/p>\n<p>Public product information includes the authorised dose, indications, contraindications and known adverse reactions. It does not necessarily include every original dose-finding study or its detailed results. We therefore need to distinguish a smaller dose having been studied and found inadequate from insufficient public data on smaller doses.<\/p>\n<p>FendaF has begun a separate investigation into the evidence underlying canine rabies vaccine doses, how safety has been assessed in dogs of different weights and health status, and how accessible this information is to owners.<\/p>\n<p>What matters to us is not only the research findings, but also manufacturers\u2019 willingness to answer substantive questions about their products. Different levels of accessible, verifiable information about two authorised vaccines can influence an owner\u2019s confidence and preference, even without establishing a difference in actual vaccine safety.<\/p>\n<p>The investigation must also distinguish refusal to disclose information from legal or commercial confidentiality restrictions, or referral to the competent authority. We will update the article once manufacturers and authorities have responded.<\/p>\n<h2>How can you make a reasoned decision for your dog?<\/h2>\n<p>A good decision starts with \u201cagainst which disease, why now, and what is this dog\u2019s benefit\u2013risk balance?\u201d rather than simply \u201cvaccinate or not?\u201d<\/p>\n<ul>\n<li>Which disease is the vaccine targeting, and how likely is exposure for this dog?<\/li>\n<li>What is the vaccination history, and could titre testing assess existing immunity to certain core diseases?<\/li>\n<li>Is the dog clinically stable at the time of vaccination?<\/li>\n<li>Has the dog had a suspected vaccine reaction before, and was it documented?<\/li>\n<li>Are all vaccines planned for this appointment needed now?<\/li>\n<li>Do age, body weight, breed or underlying conditions change the risk assessment?<\/li>\n<\/ul>\n<p>After a suspected adverse reaction, keep the vaccine name, batch number, administration date, names of other medicines or vaccines given at the same time, and the timing and description of symptoms. Photographs or veterinary test results may also be useful.<\/p>\n<p>Difficulty breathing, collapse, rapidly worsening facial swelling or other signs of a severe acute reaction after vaccination require immediate emergency veterinary attention.<\/p>\n<h2>The aim is adequate protection, not the greatest number of vaccinations<\/h2>\n<p>Vaccination helps prevent serious infectious diseases, but \u201cgenerally safe\u201d does not mean \u201crisk-free\u201d or \u201cthe same risk for every dog\u201d. Large datasets consistently show more recorded acute adverse events in smaller dogs and dogs receiving several vaccines at one visit.<\/p>\n<p>This does not establish that a smaller vaccine dose would be adequate or safer, nor that vaccines should be avoided. It means decisions must consider the individual dog, the infection risk, product characteristics, existing immunity and alternatives.<\/p>\n<p>Leptospirosis, rabies, distemper, parvovirus and other infections are not interchangeable. Neither are the evidence, duration of immunity and legal status of their vaccines. One universal statement about vaccination cannot fit every dog.<\/p>\n<p>A good vaccination decision achieves the protection an individual dog needs, accounting as carefully as possible for benefits, risks and what we still do not know.<\/p>\n<p>Sometimes the best decision begins with a simple question: why this vaccine, at this dose, right now?<\/p>\n<h2>In future articles, we will look more closely at\u2026<\/h2>\n<ul>\n<li>vaccine ingredients: antigens, adjuvants, stabilisers and manufacturing residues;<\/li>\n<li>leptospirosis in Estonia: serogroups, environmental risk, L2\/L4 coverage and diagnostic limitations;<\/li>\n<li>titre tests: what they can and cannot tell us for different diseases;<\/li>\n<li>puppy immunology and the maternal-antibody \u201cwindow of susceptibility\u201d.<\/li>\n<\/ul>\n<h2>Sources<\/h2>\n<ul>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16220670\/\">Moore GE, Guptill LF, Ward MP et al. Adverse events diagnosed within three days of vaccine administration in dogs. J Am Vet Med Assoc. 2005;227(7):1102\u20131108. PMID 16220670. DOI 10.2460\/javma.2005.227.1102.<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37451674\/\">Moore GE, Morrison J, Saito EK et al. Breed, smaller weight, and multiple injections are associated with increased adverse event reports within three days following canine vaccine administration. J Am Vet Med Assoc. 2023;261(11):1653\u20131659. PMID 37451674. DOI 10.2460\/javma.23.03.0181.<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38568777\/\">Squires RA, Crawford C, Marcondes M, Whitley N. 2024 guidelines for the vaccination of dogs and cats. J Small Anim Pract. 2024;65(5):277\u2013316. PMID 38568777. DOI 10.1111\/jsap.13718.<\/a><\/li>\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/26517617\/\">Yao PJ, Stephenson N, Foley JE et al. Incidence rates and risk factors for owner-reported adverse events following vaccination of dogs that did or did not receive a Leptospira vaccine. J Am Vet Med Assoc. 2015;247(10):1139\u20131145. PMID 26517617. DOI 10.2460\/javma.247.10.1139.<\/a><\/li>\n<li><a href=\"https:\/\/www.gov.uk\/government\/news\/vmd-reaffirms-safety-of-leptospira-vaccines-in-dogs\">Veterinary Medicines Directorate. VMD reaffirms safety of Leptospira vaccines in dogs. 5 March 2026.<\/a><\/li>\n<li><a href=\"https:\/\/www.gov.uk\/guidance\/calculation-of-adverse-event-incidence-for-veterinary-medicines\">Veterinary Medicines Directorate. Calculation of adverse event incidence for veterinary medicines.<\/a><\/li>\n<li><a href=\"https:\/\/www.riigiteataja.ee\/akt\/110122024008\">Riigi Teataja. Regulation No 14 of 11 March 2022 on detailed measures for rabies prevention and control, current version.<\/a><\/li>\n<li><a href=\"https:\/\/drjudymorgan.com\/blogs\/blog\/is-your-pet-over-vaccinated\">Judy Morgan. Is Your Pet Over-Vaccinated?<\/a><\/li>\n<li><a href=\"https:\/\/peterdobias.com\/blogs\/blog\/holistic-vet-vaccine-recommendations\">Peter Dobias. Holistic Vet Vaccine Recommendations.<\/a><\/li>\n<li><a href=\"https:\/\/peterdobias.com\/blogs\/blog\/three-harmful-myths-about-raising-puppies-part-1-socialization-and-vaccines\/\">Peter Dobias. Three Harmful Myths About Raising Puppies, Part 1: Socialization and Vaccines.<\/a><\/li>\n<li>Schultz RD. Duration of immunity for canine and feline vaccines: a review. Vet Microbiol. 2006;117(1):75\u201379. PMID 16707236. DOI 10.1016\/j.vetmic.2006.04.013. Review reporting the author\u2019s research findings. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/16707236\/\">Original source<\/a><\/li>\n<li>Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102\u2013S108. PMID 19959181. DOI 10.1016\/j.jcpa.2009.10.009. <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/19959181\/\">Original source<\/a><\/li>\n<li>Dodds WJ, Larson LJ, Christine KL, Schultz RD. Duration of immunity after rabies vaccination in dogs: The Rabies Challenge Fund research study. Can J Vet Res. 2020;84(2):153\u2013158. PMID 32255911. PMCID PMC7088826. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7088826\/\">Original source<\/a><\/li>\n<li>Peter Dobias. A complete guide to raising puppies naturally. Autori kliiniline and integratiivne k\u00e4sitlus. <a href=\"https:\/\/peterdobias.com\/blogs\/blog\/puppy-care-guide\">Source<\/a><\/li>\n<li>Judy Morgan. Start Your Babies Out Right. 13.11.2016. The author\u2019s clinical recommendation on booster timing. <a href=\"https:\/\/drjudymorgan.com\/blogs\/blog\/start-your-babies-out-right\">Source<\/a><\/li>\n<li>Judy Morgan and Rachel Fusaro. Vaccine Starter Guide. 2023. The authors\u2019 vaccination guide, not a controlled comparative study. <a href=\"https:\/\/www.rachelfusaro.com\/wp-content\/uploads\/2023\/05\/Vaccine-Starter-Guide-with-Dr.-Judy-Morgan-and-Rachel-Fusaro.pdf\">Source<\/a><\/li>\n<li>European Medicines Agency. Reporting adverse events for veterinary medicines. Guidance on reporting suspected adverse events; confirmed causation is not a prerequisite. <a href=\"https:\/\/www.ema.europa.eu\/en\/partners-networks\/animal-health-professionals\/reporting-adverse-events-veterinary-medicines\">EMA reporting guidance<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>What research shows about dog vaccination side effects, long-term immunity and antibody titres, and how to weigh the benefits and risks for your dog.<\/p>\n","protected":false},"author":3,"featured_media":190227,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[698],"tags":[],"class_list":["post-190216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"acf":[],"featured_image_src":{"landsacpe":["https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png",300,300,false],"list":["https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png",300,300,false],"medium":["https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png",300,300,false],"full":["https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png",300,300,false]},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dog vaccination side effects: risks and research | FendaF<\/title>\n<meta name=\"description\" content=\"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dog vaccination side effects: risks and research | FendaF\" \/>\n<meta property=\"og:description\" content=\"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/\" \/>\n<meta property=\"og:site_name\" content=\"FendaF - thinking of your pet!\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fendafmaius\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-19T06:18:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-16T20:15:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Piret Oper\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@piret.oper\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Piret Oper\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/\"},\"author\":{\"name\":\"Piret Oper\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/person\\\/bac9e619d6199be4b1614eba36ac7c34\"},\"headline\":\"Dog vaccination side effects: what studies show and how to assess your dog\u2019s risk\",\"datePublished\":\"2021-02-19T06:18:05+00:00\",\"dateModified\":\"2026-10-16T20:15:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/\"},\"wordCount\":4982,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/FendaF_vaktsineerimine_EN_300x300.png\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/\",\"name\":\"Dog vaccination side effects: risks and research | FendaF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/FendaF_vaktsineerimine_EN_300x300.png\",\"datePublished\":\"2021-02-19T06:18:05+00:00\",\"dateModified\":\"2026-10-16T20:15:48+00:00\",\"description\":\"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/FendaF_vaktsineerimine_EN_300x300.png\",\"contentUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/FendaF_vaktsineerimine_EN_300x300.png\",\"width\":300,\"height\":300,\"caption\":\"Brown dog beside a syringe with the heading \u201cDog vaccination side effects\u201d\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/vaktsineerimise-korvalmojud\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dog vaccination side effects: what studies show and how to assess your dog\u2019s risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/\",\"name\":\"FendaF - thinking of your pet!\",\"description\":\"Treats and quality dry food for your pet\",\"publisher\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\",\"name\":\"FendaF O\u00dc\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Fendaf_logo_taustata.png\",\"contentUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Fendaf_logo_taustata.png\",\"width\":7262,\"height\":4799,\"caption\":\"FendaF O\u00dc\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/fendafmaius\\\/\",\"https:\\\/\\\/www.instagram.com\\\/fendaf.ee\\\/\",\"https:\\\/\\\/www.pinterest.com\\\/3a00893ff1d6c42bef9ee783f17b79\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/person\\\/bac9e619d6199be4b1614eba36ac7c34\",\"name\":\"Piret Oper\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"caption\":\"Piret Oper\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/explore\\\/tags\\\/fendafmaius\\\/\",\"https:\\\/\\\/x.com\\\/piret.oper\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dog vaccination side effects: risks and research | FendaF","description":"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/","og_locale":"en_US","og_type":"article","og_title":"Dog vaccination side effects: risks and research | FendaF","og_description":"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.","og_url":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/","og_site_name":"FendaF - thinking of your pet!","article_publisher":"https:\/\/www.facebook.com\/fendafmaius\/","article_published_time":"2021-02-19T06:18:05+00:00","article_modified_time":"2026-10-16T20:15:48+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","type":"image\/png"}],"author":"Piret Oper","twitter_card":"summary_large_image","twitter_creator":"@piret.oper","twitter_misc":{"Written by":"Piret Oper","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#article","isPartOf":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/"},"author":{"name":"Piret Oper","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/person\/bac9e619d6199be4b1614eba36ac7c34"},"headline":"Dog vaccination side effects: what studies show and how to assess your dog\u2019s risk","datePublished":"2021-02-19T06:18:05+00:00","dateModified":"2026-10-16T20:15:48+00:00","mainEntityOfPage":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/"},"wordCount":4982,"commentCount":0,"publisher":{"@id":"https:\/\/fendaf.ee\/en\/#organization"},"image":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#primaryimage"},"thumbnailUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/","url":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/","name":"Dog vaccination side effects: risks and research | FendaF","isPartOf":{"@id":"https:\/\/fendaf.ee\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#primaryimage"},"image":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#primaryimage"},"thumbnailUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","datePublished":"2021-02-19T06:18:05+00:00","dateModified":"2026-10-16T20:15:48+00:00","description":"Dog vaccination side effects explained: small dogs, multiple vaccines, leptospirosis, antibody titres and lasting immunity. Assess your dog\u2019s individual risk.","breadcrumb":{"@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#primaryimage","url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","contentUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","width":300,"height":300,"caption":"Brown dog beside a syringe with the heading \u201cDog vaccination side effects\u201d"},{"@type":"BreadcrumbList","@id":"https:\/\/fendaf.ee\/en\/health\/vaktsineerimise-korvalmojud\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fendaf.ee\/en\/"},{"@type":"ListItem","position":2,"name":"Dog vaccination side effects: what studies show and how to assess your dog\u2019s risk"}]},{"@type":"WebSite","@id":"https:\/\/fendaf.ee\/en\/#website","url":"https:\/\/fendaf.ee\/en\/","name":"FendaF - thinking of your pet!","description":"Treats and quality dry food for your pet","publisher":{"@id":"https:\/\/fendaf.ee\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fendaf.ee\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fendaf.ee\/en\/#organization","name":"FendaF O\u00dc","url":"https:\/\/fendaf.ee\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2020\/03\/Fendaf_logo_taustata.png","contentUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2020\/03\/Fendaf_logo_taustata.png","width":7262,"height":4799,"caption":"FendaF O\u00dc"},"image":{"@id":"https:\/\/fendaf.ee\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/fendafmaius\/","https:\/\/www.instagram.com\/fendaf.ee\/","https:\/\/www.pinterest.com\/3a00893ff1d6c42bef9ee783f17b79\/"]},{"@type":"Person","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/person\/bac9e619d6199be4b1614eba36ac7c34","name":"Piret Oper","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","caption":"Piret Oper"},"sameAs":["https:\/\/www.instagram.com\/explore\/tags\/fendafmaius\/","https:\/\/x.com\/piret.oper"]}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2021\/02\/FendaF_vaktsineerimine_EN_300x300.png","_links":{"self":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/190216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/comments?post=190216"}],"version-history":[{"count":2,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/190216\/revisions"}],"predecessor-version":[{"id":190228,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/190216\/revisions\/190228"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/media\/190227"}],"wp:attachment":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/media?parent=190216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/categories?post=190216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/tags?post=190216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}